Adjusted Earnings Per Share: Pfizer has maintained its adjusted earnings per share outlook for 2025, indicating a steady operational performance. Revenue Forecast Revision: The downward adjustment in ...

Pfizer CEO Albert Bourla defended his company’s vaccine business as rhetoric from HHS Secretary Robert F. Kennedy Jr. drives ...

As 2025 closes out, a pair of autoimmune biotechs have eked out separate deals with Big Pharma before year-end, each with a sizable potential payout down the line. | Seattle’s Adaptive Biotechnologies ...

Replicate Bioscience, a clinical-stage company pioneering novel self-replicating RNA (srRNA) technology for applications across infectious disease, immunology, and other therapeutic areas, today ...

Ascentage Pharma's first approved product, Olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in ...

Pfizer is in the midst of an aggressive, multi-year cost-cutting effort, which so far has left nearly 2,000 people jobless.

UST has signed a Memorandum of Understanding (MoU) with the IIT Madras Incubation Cell (IITMIC), deep tech startup hub ...

Pfizer's latest narrative update leaves its fair value estimate steady at about $29.08 per share, even as analysts fine tune assumptions around the company’s long term trajectory. Slightly softer ...

Also in today’s newsletter: oil prices tumble on hopes for a Ukraine peace deal and dealmakers gear up for busy year end ...

UST, a leading AI and technology transformation solutions company, has signed a Memorandum of Understanding (MoU) with the IIT Madras Incubation Cell (IITMIC), India's premier deep tech startup hub ...

The U.S. health regulator on Friday approved Innoviva's oral antibiotic to treat gonorrhea, a common sexually transmitted ...

The "Malabsorption Syndrome Market - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global market for Malabsorption Syndrome was valued at US$3.5 Billion in ...